Extracellular Vesicle (EV) Survivin for Cancer Diagnostics and Therapeutics: A Review
Authors:
Open Access
- 22 August 2024
- journal article
- review article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 29 (8) , 302
Abstract
Survivin, an important inhibitor of apoptosis protein, contributes to cancer cells’ resistance to apoptosis, proliferation, and survival. It is a promising biomarker and therapeutic target due to being highly expressed in cancer cells relative to normal cells and universally expressed in almost all cancer types. Cancer cells release survivin to the tumour microenvironment (TME) not only as a free protein but also encapsulated in extracellular vesicles (EVs), especially small EVs (sEVs). The release of encapsulated survivin from cancer cells can be taken up by neighbouring cells, eliciting pathological responses such as tumorigenesis and metastasis. Consequently, EV survivin holds potential as a diagnostic, prognostic, and therapeutic biomarker for several types of cancer, including breast cancer, prostate cancer, pancreatic cancer, and glioblastoma. EV survivin expression is significantly elevated in cancer patients and correlates with unfavourable clinicopathologic parameters. Although no clinical studies have explored EV survivin as a therapeutic target, future research should explore survivin-based therapies in combination with EV-targeting therapies to effectively disrupt its roles in tumorigenesis and metastasis.Keywords
This publication has 137 references indexed in Scilit:
- Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1Advanced Science, 2021
- Effects of poly(I:C) and MF59 co‐adjuvants on immunogenicity and efficacy of survivin polypeptide immunogen against melanomaJournal of Cellular Physiology, 2017
- Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinomaHepatology, 2017
- Apoptotic Bodies: Selective Detection in Extracellular Vesicles2017
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant gliomaCancer Immunology, Immunotherapy, 2016
- Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and UptakeCellular and Molecular Neurobiology, 2016
- Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP)Cancer Microenvironment, 2015
- A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphomaCancer, 2011
- Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2010
- Survivin is released from cancer cells via exosomesApoptosis, 2010